Kyndred spirits

Why Atlas, OrbiMed created a separate company for immunometabolism asset ARY-007

Partners Kyn Therapeutics Inc. and Arrys Therapeutics Inc. share an investor syndicate and a focus on cancer therapies targeting metabolic pathways in immune cells. However, the companies are keeping their assets separate to keep the door open for different funding strategies as

Read the full 425 word article

User Sign In